Board appointment at Genocea Biosciences
This article was originally published in Scrip
Executive Summary
The US vaccine discovery and development company Genocea Biosciences has appointed Mustapha Leavenworth Bakali to its board of directors as executive director. Over the past 20 years, Mr Bakali has held senior operating and leadership positions at ID Biomedical (acquired by GlaxoSmithKline), PowderJect Pharmaceuticals (acquired by Chiron), Chiron Vaccines (acquired by Novartis), and is a board member at Intercell.